New York Life Investment Management LLC Buys 789 Shares of Gilead Sciences, Inc. $GILD

New York Life Investment Management LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 187,571 shares of the biopharmaceutical company’s stock after acquiring an additional 789 shares during the period. New York Life Investment Management LLC’s holdings in Gilead Sciences were worth $20,796,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of GILD. Smallwood Wealth Investment Management LLC bought a new position in shares of Gilead Sciences in the first quarter worth about $25,000. Activest Wealth Management raised its stake in shares of Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the last quarter. GoalVest Advisory LLC raised its stake in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the last quarter. Harbor Asset Planning Inc. bought a new position in shares of Gilead Sciences in the second quarter worth about $27,000. Finally, Colonial Trust Advisors raised its stake in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 213 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Down 0.4%

Gilead Sciences stock opened at $120.47 on Tuesday. The company has a market cap of $149.48 billion, a P/E ratio of 24.00, a price-to-earnings-growth ratio of 0.83 and a beta of 0.34. Gilead Sciences, Inc. has a 1-year low of $86.08 and a 1-year high of $124.61. The company has a fifty day simple moving average of $115.52 and a 200 day simple moving average of $111.21. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter last year, the firm earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. TD Cowen boosted their price target on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. BMO Capital Markets boosted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a research note on Monday, October 20th. Citigroup boosted their price target on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Wednesday, October 8th. Finally, Royal Bank Of Canada boosted their price target on shares of Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $122.61.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Monday, September 29th. The shares were sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the sale, the chief executive officer owned 591,203 shares in the company, valued at $66,013,726.98. This trade represents a 1.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $354,240.00. Following the completion of the sale, the insider owned 110,193 shares of the company’s stock, valued at approximately $13,011,589.44. This represents a 2.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 61,500 shares of company stock worth $7,142,140 over the last quarter. 0.27% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.